CLYM · Climb Bio, Inc.

The departure of Cindy Driscoll as Senior Vice President, Finance and principal accounting officer represents a significant change in the company's financial leadership structure. Her separation, described as mutually agreed upon, will be effective April 30, 2026. In response, the company has consolidated accounting oversight under existing CFO Dr. Susan Altschuller, who will now serve as both principal financial officer and principal accounting officer. This consolidation suggests potential operational streamlining in the finance department. Dr. Altschuller brings relevant experience from previous CFO roles at biotechnology companies including Dragonfly Therapeutics, Cerevel Therapeutics, and ImmunoGen, having joined Climb Bio as CFO in October 2025. The filing explicitly states no changes were made to her compensation arrangements in connection with this expanded role, indicating this represents an internal reassignment of duties rather than a new executive appointment requiring revised compensation terms.